Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Tempest Therapeutics, Inc. (TPST)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6900+0.1600 (+10.46%)
At close: 04:00PM EST
1.7100 +0.02 (+1.18%)
After hours: 04:18PM EST
Advertisement

Tempest Therapeutics, Inc.

7000 Shoreline Court
Suite 275
South San Francisco, CA 94080
United States
415 798 8589
https://www.tempesttx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees17

Key Executives

NameTitlePayExercisedYear Born
Mr. Stephen R. Brady J.D., LLMCEO & Director665.4kN/A1970
Dr. Thomas W. Dubensky Jr., Ph.D.Pres & Director938.07kN/A1958
Dr. Samuel Whiting M.D., Ph.D.Exec. VP & Chief Medical Officer540kN/AN/A
Mr. Nicholas MaestasVP of Strategy & Fin. and Sec.N/AN/A1980
Mr. Justin TrojanowskiCorp. Controller, Treasurer & Principal Accounting OfficerN/AN/A1988
Mr. Petpiboon PrasitActing Chief Scientific Officer & Exec. DirectorN/AN/AN/A
Dr. Sharon Sakai Ph.D., RACHead of Regulatory & QualityN/AN/AN/A
Dr. Anne MoonSr. VP and Head of Project Team Leadership, Project Management & Portfolio ManagementN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Corporate Governance

Tempest Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement